Ajanta Pharma is currently trading at Rs. 1782.60, up by 54.10 points or 3.13% from its previous ...
Result Synopsis Ajanta reported a robust quarter with stellar beat on margin and all round gro...
About the stock: Ajanta Pharma is a focused player in branded generics, which constitutes ~72% of...
Ajanta Pharma is currently trading at Rs. 1421.35, up by 20.70 points or 1.48% from its previous ...
Result Synopsis Ajanta Pharma reported a largely inline quarter – slight miss on margin ...
*We met with the management of Ajanta Pharma (AJP) recently to understand its business outlook in...
Healthy Work-in-progress on reducing cost pressure to boost outlook * We met with the manageme...
Margin concerns behind; growth intact Result Synopsis Ajanta Pharma clocked an in-line reve...
Growth momentum intact; maintaining a Buy Powered by strong growth (on the Covid-impacted low ...
The company reported standalone net profit of Rs 150.37 crore for the quarter ended June 30, 2022...
US approvals can drive rerating Result Synopsis Ajanta clocked 15% growth in 4Q, higher tha...
Robust outlook in the Branded Generics segment Slow pace of ANDA filings to hinder US growth o...
Momentum in branded business buoys numbers… About the stock: Ajanta Pharma is a focused...
Strong performance on all fronts… About the stock: Ajanta Pharma is a focused player in...
Key earnings drivers intact Our view A strong revenue quarter with some one-off strength in...
DF, US, Africa drive revenue growth US ANDA filings to improve going forward * Ajanta Pharm...
Buy Ajanta Pharmaceuticals Ltd For Target Rs.2695 India growth drives steady numbers… ...
The company reported standalone net profit of Rs 193.46 crore for the quarter ended June 30, 2021...
Below is quote on Ajanta pharma reported numbers in line with market expectation for Q1...
Our view Ajanta Pharma performed in line with expectation on revenues and margin. We see a fir...
Buy Ajanta Pharma Ltd For Target Rs.2,150 DF, Institutional Anti-Malaria drive earnings US ...
Result Highlights * Strong performance across the board; India, US clocked 20% growth while In...
The company reported standalone net profit of Rs 154.78 crore for the quarter ended March 31, 202...
Poised to re-rate Ajanta’s Q3 revenue grew by 15% YoY driven by strong performance in br...
Domestic rebound drives EPS upgrade ‐ BUY stays Our view: Ajanta Pharma has revised ...
Below are Quote On Ajanta Pharma 3QFY21 By Mr. Yash Gupta Equity Researc...